Literature DB >> 20590560

Animal models of cannabinoid reward.

Leigh V Panlilio1, Zuzana Justinova, Steven R Goldberg.   

Abstract

The endogenous cannabinoid system is involved in numerous physiological and neuropsychological functions. Medications that target this system hold promise for the treatment of a wide variety of disorders. However, as reward is one of the most prominent of these functions, medications that activate this system must be evaluated for abuse potential. Meanwhile, cannabis is already being used chronically by millions of people, many of whom eventually seek treatment for cannabis dependence. Therefore, there is a need for procedures that can be used to: (i) better understand the mechanisms of cannabinoid reward; (ii) evaluate the abuse potential of new medications; and (iii) evaluate the effectiveness of medications developed for treating cannabis dependence. Animal models of cannabinoid reward provide a means of accomplishing these goals. In this review, we briefly describe and evaluate these models, their advantages and their shortcomings. Special emphasis is placed on intravenous cannabinoid self-administration in squirrel monkeys, a valid, reliable and flexible model that we have developed over the past decade. Although the conditions under which cannabinoid drugs have rewarding effects may be more restricted than with other drugs of abuse such as cocaine and heroin, work with these models indicates that cannabinoid reward involves similar brain mechanisms and produces the same kinds of reward-related behaviour. By continuing to use these animal models as tools in the development of new medications, it should be possible to take advantage of the potential benefits provided by the endocannabinoid system while minimizing its potential for harm.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20590560      PMCID: PMC2931551          DOI: 10.1111/j.1476-5381.2010.00775.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  110 in total

1.  Involvement of kappa/dynorphin system in WIN 55,212-2 self-administration in mice.

Authors:  Victoria Mendizábal; Andreas Zimmer; Rafael Maldonado
Journal:  Neuropsychopharmacology       Date:  2005-11-16       Impact factor: 7.853

2.  Cannabinoid self-administration increases dopamine release in the nucleus accumbens.

Authors:  Paola Fadda; Maria Scherma; Maria Sabrina Spano; Paola Salis; Valeria Melis; Liana Fattore; Walter Fratta
Journal:  Neuroreport       Date:  2006-10-23       Impact factor: 1.837

3.  Dose-related differences in the regional pattern of cannabinoid receptor adaptation and in vivo tolerance development to delta9-tetrahydrocannabinol.

Authors:  Diana L McKinney; Michael P Cassidy; Lauren M Collier; Billy R Martin; Jenny L Wiley; Dana E Selley; Laura J Sim-Selley
Journal:  J Pharmacol Exp Ther       Date:  2007-10-29       Impact factor: 4.030

4.  The orphan receptor GPR55 is a novel cannabinoid receptor.

Authors:  E Ryberg; N Larsson; S Sjögren; S Hjorth; N-O Hermansson; J Leonova; T Elebring; K Nilsson; T Drmota; P J Greasley
Journal:  Br J Pharmacol       Date:  2007-09-17       Impact factor: 8.739

5.  Previous exposure to THC alters the reinforcing efficacy and anxiety-related effects of cocaine in rats.

Authors:  Leigh V Panlilio; Marcello Solinas; Stephanie A Matthews; Steven R Goldberg
Journal:  Neuropsychopharmacology       Date:  2006-05-31       Impact factor: 7.853

6.  Monitoring extracellular dopamine in the rat nucleus accumbens shell and core during acquisition and maintenance of intravenous WIN 55,212-2 self-administration.

Authors:  Daniele Lecca; Fabio Cacciapaglia; Valentina Valentini; Gaetano Di Chiara
Journal:  Psychopharmacology (Berl)       Date:  2006-07-19       Impact factor: 4.530

7.  Strain and schedule-dependent differences in the acquisition, maintenance and extinction of intravenous cannabinoid self-administration in rats.

Authors:  Serena Deiana; Liana Fattore; M Sabrina Spano; Gregorio Cossu; Emanuele Porcu; Paola Fadda; Walter Fratta
Journal:  Neuropharmacology       Date:  2006-11-13       Impact factor: 5.250

8.  A stimulus-control account of regulated drug intake in rats.

Authors:  Leigh V Panlilio; Eric B Thorndike; Charles W Schindler
Journal:  Psychopharmacology (Berl)       Date:  2007-10-24       Impact factor: 4.530

9.  Cannabinoid self-administration in rats: sex differences and the influence of ovarian function.

Authors:  L Fattore; M S Spano; S Altea; F Angius; P Fadda; W Fratta
Journal:  Br J Pharmacol       Date:  2007-09-24       Impact factor: 8.739

Review 10.  Self-administration of drugs in animals and humans as a model and an investigative tool.

Authors:  Leigh V Panlilio; Steven R Goldberg
Journal:  Addiction       Date:  2007-12       Impact factor: 6.526

View more
  16 in total

1.  Themed issue: cannabinoids.

Authors:  S P H Alexander; K Mackie; R A Ross
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

Review 2.  Cannabinoid-related agents in the treatment of anxiety disorders: current knowledge and future perspectives.

Authors:  Simone Tambaro; Marco Bortolato
Journal:  Recent Pat CNS Drug Discov       Date:  2012-04-01

Review 3.  Screening Medications for the Treatment of Cannabis Use Disorder.

Authors:  L V Panlilio; Z Justinova; J M Trigo; B Le Foll
Journal:  Int Rev Neurobiol       Date:  2016-03-10       Impact factor: 3.230

Review 4.  Intracranial self-stimulation to evaluate abuse potential of drugs.

Authors:  S Stevens Negus; Laurence L Miller
Journal:  Pharmacol Rev       Date:  2014-07       Impact factor: 25.468

5.  Reinforcing and neurochemical effects of cannabinoid CB1 receptor agonists, but not cocaine, are altered by an adenosine A2A receptor antagonist.

Authors:  Zuzana Justinová; Sergi Ferré; Godfrey H Redhi; Paola Mascia; Jessica Stroik; Davide Quarta; Sevil Yasar; Christa E Müller; Rafael Franco; Steven R Goldberg
Journal:  Addict Biol       Date:  2010-11-04       Impact factor: 4.280

6.  The fatty acid amide hydrolase inhibitor URB 597: interactions with anandamide in rhesus monkeys.

Authors:  Jennifer L Stewart; Lance R McMahon
Journal:  Br J Pharmacol       Date:  2011-09       Impact factor: 8.739

Review 7.  Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ9-Tetrahydrocannabinol.

Authors:  Douglas L Boggs; Jacques D Nguyen; Daralyn Morgenson; Michael A Taffe; Mohini Ranganathan
Journal:  Neuropsychopharmacology       Date:  2017-09-06       Impact factor: 7.853

8.  The Pharmacological Inhibition of Fatty Acid Amide Hydrolase Prevents Excitotoxic Damage in the Rat Striatum: Possible Involvement of CB1 Receptors Regulation.

Authors:  Gabriela Aguilera-Portillo; Edgar Rangel-López; Juana Villeda-Hernández; Anahí Chavarría; Pilar Castellanos; Zubeyir Elmazoglu; Çimen Karasu; Isaac Túnez; Gibrán Pedraza; Mina Königsberg; Abel Santamaría
Journal:  Mol Neurobiol       Date:  2018-05-25       Impact factor: 5.590

9.  Pharmacokinetic and Pharmacodynamic Characterization of Tetrahydrocannabinol-Induced Cannabinoid Dependence After Chronic Passive Cannabis Smoke Exposure in Rats.

Authors:  Abhigyan Ravula; Hardik Chandasana; Darin Jagnarine; Shannon C Wall; Barry Setlow; Marcelo Febo; Adriaan W Bruijnzeel; Hartmut Derendorf
Journal:  Cannabis Cannabinoid Res       Date:  2019-12-06

10.  International Association for the Study of Pain Presidential Task Force on Cannabis and Cannabinoid Analgesia: research agenda on the use of cannabinoids, cannabis, and cannabis-based medicines for pain management.

Authors:  Simon Haroutounian; Lars Arendt-Nielsen; Joletta Belton; Fiona M Blyth; Louisa Degenhardt; Marta Di Forti; Christopher Eccleston; David P Finn; Nanna B Finnerup; Emma Fisher; Alexandra E Fogarty; Ian Gilron; Andrea G Hohmann; Eija Kalso; Elliot Krane; Mohammed Mohiuddin; R Andrew Moore; Michael Rowbotham; Nadia Soliman; Mark Wallace; Nantthasorn Zinboonyahgoon; Andrew S C Rice
Journal:  Pain       Date:  2021-07-01       Impact factor: 6.961

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.